Liquid biopsy, which is collected through a blood draw, is used in patients with breast cancer to assess DNA mutations in genes such as PIK3CA and ESR1, which have FDA-approved targeted therapeutic interventions [24,25]. The gene discussed is ESR1; the disease is breast carcinoma.